Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Panacea Biotec Ltd - 531349 - Notice Of Extraordinary General Meeting And Details Of Cut-Off Date For E-Voting And E-Voting Period

 In continuation to our earlier letter dated 14.02.2020, pursuant to Regulation 30 of SEBI LODR Regulations, 2015, we would like to inform you that an EGM of the Company is scheduled to be held on Saturday, 28.03.2020 at 11:30 A.M. at the Registered Office of the Company at Ambala-Chandigarh Highway, Lalru - 140501, Punjab. Further, pursuant to the provisions of Section 108 of the Act and Reg 44 of the SEBI LODR Regulations, 2015, the Company is pleased to provide remote e-voting facility to its members to cast their votes electronically on all resolutions set forth in enclosed Notice. You are also requested to take on record the following: 1.The cut-off date for the purpose of exercising remote e-voting facility shall be Saturday, 21.03.2020. 2.The remote e-voting period shall commence on Wednesday, 25.03.2020 and (from 09:00 a.m. IST) and end on Friday, 27.03.2020 (upto 05:00 p.m. IST).
04-03-2020
Bigul

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our letter dated February 14, 2020 for approving the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2019 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of Extract of Statement of aforesaid Unaudited Financial Results, published in the following newspapers on February 15,2020:- Business Standard (English); Desh Sewak (Punjabi) This is for your kind information and record please.
15-02-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Outcome of Board Meeting (EGM on March 28, 2020)

 Panacea Biotec Ltd has informed BSE about Outcome of Board Meeting held on February 14, 2020.
14-02-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release - 'Unaudited Financial Results for the Quarter & Nine Months ended December 31, 2019' This is in continuation to our letter dated February 14, 2020, along with the copy of Standalone and Consolidated Unaudited Financial Results (Provisional) of the Company for the quarter and nine months ended December 31, 2019, as reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on February 14, 2020. Panacea Biotec is now delighted to attach a copy of the Press Release showing the key highlights of the financial results for the quarter and nine months ended December 31, 2019, being released to media, etc. in this regard.
14-02-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Outcome Of Board Meeting

 Pursuant to Reg 30 of SEBI LODR Regulations, the Board of Directors of the Company has, at its meeting held today, i.e. 14.02. 2020, inter-alia, considered and approved the following:- 1. Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and nine months ended 31.12. 2019 in terms of Regulation 33 of SEBI LODR Regulations. The same were also reviewed by the Audit Committee in its meeting held earlier on 14.02.2020. 2. Subject to the approval of the Shareholders of the Company, Panacea Biotec Limited - Employee Stock Option Plan 2020 ('ESOP 2020'/ 'Plan') for the Employees of the company and its subsidiary company; and 3.An EGM of the Company will be held on Saturday, 28.03.2020 at 11:30 A.M. at the Registered Office of the Company. The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 5:40 P.M.
14-02-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Unaudited Standalone And Consolidated Financial Results (Provisional)For The Quarter And Nine Months Ended December 31, 2019

 Pursuant to Reg 30 of SEBI LODR Regulations, the Board of Directors of the Company has, at its meeting held today, i.e. 14.02.2020, inter-alia, considered and approved the following:- 1.Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and nine months ended 31.12. 2019 in terms of Regulation 33 of SEBI LODR Regulations. The same were also reviewed by the Audit Committee in its meeting held earlier on 14.02.2020. 2.Subject to the approval of the Shareholders of the Company, Panacea Biotec Limited - Employee Stock Option Plan 2020 ('ESOP 2020'/ 'Plan') for the Employees of the company and its subsidiary company; and 3.An EGM of the Company will be held on Saturday, 28.03.2020 at 11:30 A.M. at the Registered Office of the Company. The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 5:40 P.M.
14-02-2020
Bigul

Panacea Biotec Ltd - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we are enclosing herewith the data of shares dematerialized during the month of January, 2020 as Annexure - 1. We would also like to confirm that the total number of shares dematerialized as on January 31, 2020, were as under: NSDL 57,212,553 CDSL 3,814,942 Total 61,027,495 A copy of the certificate obtained from the Company's RTA viz. Skyline Financial Services Pvt. Ltd., regarding shares dematerialized as on January 31, 2020 is also enclosed as Annexure - 2. This is for your information and record please. Kindly acknowledge the receipt.
07-02-2020
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our letter dated February 05, 2020 intimating the date of proposed Board Meeting scheduled to be held on February 14, 2020, for approving the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2019 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of the notice of Board Meeting published in the following newspapers on February 07, 2020:- Business Standard (English); Desh Sewak (Punjabi) This is for your kind information and record please.
07-02-2020
Bigul

Panacea Biotec Ltd - 531349 - Board Meeting Intimation for Approving The Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended December 31, 2019

 PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI LODR Regulations, 2015, this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 14.02.2020 at New Delhi, inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended 31.12.2019. Further, with reference to our earlier announcement dated 30.12.2019 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading under SEBI PIT Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company and Material Subsidiaries of the Company till 16.02.2020. This is for your kind information and record please.
05-02-2020
Bigul

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release - Panacea Biotec Limited completes transfer of its Pharmaceuticals Business to its wholly owned subsidiary 'Panacea Biotec Pharma Limited' Panacea Biotec Ltd. is pleased to announce that the company has completed transfer of its Pharmaceuticals Business by way of slump sale (as a going concern) to its wholly-owned subsidiary viz. Panacea Biotec Pharma Limited ('PBPL'), with an objective to streamline operations and create inherent focus among the businesses of the Company. PBPL obtained the drug manufacturing license on 01.02.2020. Pursuant to above and in compliance with the terms and conditions of the BTA, the transfer of the Company's pharmaceuticals business to PBPL by way of slump sale as a going concern has become effective from 01.02.2020. The documents relating to closing of transaction as above were executed on 04.02.2020. A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please.
05-02-2020
Next Page
Close

Let's Open Free Demat Account